Back to Search Start Over

Improving radiotherapy in immunosuppressive microenvironments by targeting complement receptor C5aR1

Authors :
Beach, Callum
MacLean, David
Majorova, Dominika
Melemenidis, Stavros
Nambiar, Dhanya K.
Kim, Ryan K.
Valbuena, Gabriel N.
Guglietta, Silvia
Krieg, Carsten
Darvish-Damavandi, Mahnaz
Suwa, Tatsuya
Easton, Alistair
Hillson, Lily V.S.
McCulloch, Ashley K.
McMahon, Ross K.
Pennel, Kathryn
Edwards, Joanne
O'Cathail, Sean M.
Roxburgh, Campbell S.
Domingo, Enric
Moon, Eui Jung
Jiang, Dadi
Jiang, Yanyan
Zhang, Qingyang
Koong, Albert C.
Woodruff, Trent M.
Graves, Edward E.
Maughan, Tim
Buczacki, Simon J.A.
Stucki, Manuel
Le, Quynh-Thu
Leedham, Simon J.
Giaccia, Amato J.
Olcina, Monica M.
Source :
Journal of Clinical Investigation. December, 2023, Vol. 133 Issue 23
Publication Year :
2023

Abstract

An immunosuppressive microenvironment causes poor tumor T cell infiltration and is associated with reduced patient overall survival in colorectal cancer. How to improve treatment responses in these tumors is still a challenge. Using an integrated screening approach to identify cancer-specific vulnerabilities, we identified complement receptor C5aR1 as a druggable target, which when inhibited improved radiotherapy, even in tumors displaying immunosuppressive features and poor [CD8.sup.+] T cell infiltration. While C5aR1 is well-known for its role in the immune compartment, we found that C5aR1 is also robustly expressed on malignant epithelial cells, highlighting potential tumor cell-specific functions. C5aR1 targeting resulted in increased NF-[kappa]B-dependent apoptosis specifically in tumors and not normal tissues, indicating that, in malignant cells, C5aR1 primarily regulated cell fate. Collectively, these data revealed that increased complement gene expression is part of the stress response mounted by irradiated tumors and that targeting C5aR1 could improve radiotherapy, even in tumors displaying immunosuppressive features.<br />Introduction The composition of the tumor microenvironment (TME) affects treatment responses in cancer (1-3). Immunosuppressive TME features, which act as a barrier to extensive [CD8.sup.+] T cell infiltration typically characterize [...]

Details

Language :
English
ISSN :
00219738
Volume :
133
Issue :
23
Database :
Gale General OneFile
Journal :
Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsgcl.777600278
Full Text :
https://doi.org/10.1172/JCI168277